Financial Gravity Wealth Inc. boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,825 shares of the medical research company’s stock after acquiring an additional 327 shares during the period. Amgen accounts for 0.8% of Financial Gravity Wealth Inc.’s portfolio, making the stock its 19th largest holding. Financial Gravity Wealth Inc.’s holdings in Amgen were worth $720,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Principal Financial Group Inc. grew its stake in Amgen by 1.4% during the first quarter. Principal Financial Group Inc. now owns 1,187,759 shares of the medical research company’s stock valued at $202,489,000 after acquiring an additional 15,948 shares in the last quarter. Fisher Asset Management LLC grew its stake in Amgen by 2.0% during the second quarter. Fisher Asset Management LLC now owns 149,006 shares of the medical research company’s stock valued at $27,505,000 after acquiring an additional 2,942 shares in the last quarter. Hudson Valley Investment Advisors Inc. ADV grew its stake in Amgen by 3.8% during the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 12,166 shares of the medical research company’s stock valued at $2,246,000 after acquiring an additional 445 shares in the last quarter. Capital Investment Advisors LLC grew its stake in Amgen by 8.7% during the second quarter. Capital Investment Advisors LLC now owns 24,102 shares of the medical research company’s stock valued at $4,449,000 after acquiring an additional 1,919 shares in the last quarter. Finally, Osborn Williams & Donohoe LLC grew its stake in Amgen by 1.3% during the second quarter. Osborn Williams & Donohoe LLC now owns 24,756 shares of the medical research company’s stock valued at $4,570,000 after acquiring an additional 322 shares in the last quarter. 82.37% of the stock is owned by institutional investors.
Several research firms recently weighed in on AMGN. JPMorgan Chase & Co. raised their target price on shares of Amgen from $191.00 to $192.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. Goldman Sachs Group reissued a “buy” rating and issued a $221.00 price objective on shares of Amgen in a research note on Wednesday, October 31st. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $223.00 price objective on shares of Amgen in a research note on Wednesday, October 31st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $204.55.
Amgen stock opened at $190.75 on Wednesday. The stock has a market capitalization of $119.20 billion, a PE ratio of 13.48, a PEG ratio of 1.95 and a beta of 1.37. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. The firm had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business earned $3.27 EPS. Research analysts forecast that Amgen, Inc. will post 14.24 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be issued a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 annualized dividend and a dividend yield of 2.77%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
COPYRIGHT VIOLATION NOTICE: “Amgen, Inc. (AMGN) Shares Bought by Financial Gravity Wealth Inc.” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/07/amgen-inc-amgn-shares-bought-by-financial-gravity-wealth-inc.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: How Do Tariffs Affect Trade Balances?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.